New hope: HIV drug studied in liver transplant patients

NCT ID NCT01022476

First seen Apr 13, 2026 · Last updated May 15, 2026 · Updated 4 times

Summary

This study looked at how the HIV medicine raltegravir works in people with severe liver failure who need a liver transplant. It included 14 HIV-positive adults with end-stage liver disease. Researchers measured how the drug behaves in the body and checked for interactions with anti-rejection medicines after transplant.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Service de Médecine Interne, Hôpital de Bicêtre

    Le Kremlin-Bicêtre, 94275, France

Conditions

Explore the condition pages connected to this study.